Advertisement

Neuropathic symptoms, physical and emotional well-being, and quality of life at the end of life

  • Cindy TofthagenEmail author
  • Constance Visovsky
  • Sara Dominic
  • Susan McMillan
Original Article
  • 32 Downloads

Abstract

The purpose of this cross-sectional, descriptive study was to assess differences in neuropathic symptoms, physical and emotional well-being, and quality of life in cancer patients at the end of life compared to those without neuropathic symptoms. Neuropathic symptoms were defined as numbness and tingling in the hands and/or feet. A secondary analysis of data from two hospices in Central Florida was performed. Adults (n = 717) with a cancer diagnosis, an identified family caregiver, and who were receiving hospice services, were eligible. The prevalence of numbness/tingling in the hands or feet was 40% in this sample of hospice patients with cancer. Participants with neuropathic symptoms of numbness/tingling had a significantly higher prevalence of pain (76.7% vs. 67.0%; p = .006), difficulty with urination (29.4% vs. 20.3%; p = .007), shortness of breath (64.9% vs. 54.1%; p = .005), dizziness/lightheadedness (46.0% vs. 28.2%; p < .001), sweats (35.5% vs. 20.3%; p < .001), worrying (50.7% vs. 37.3%; p = .001), feeling irritable (38.5% vs. 28.7%; p = .008), feeling sad (48.2% vs. 37.8%; p = .008), and difficulty concentrating (46.2% vs. 32.5%; p < .001). They also reported significantly higher overall symptom intensity and symptom distress scores (p = < .001), higher pain severity (p = .001) and pain distress (p = .002), and decreased quality of life (p = .002) compared to those without numbness/tingling. Neuropathic symptoms are emotionally distressing at the end of life and associated with higher symptom burden and diminished quality of life.

Keywords

Supportive care Palliative care Symptom management 

Notes

Compliance with ethical standards

The project was approved by the administrators of the two involved hospices and by the University of South Florida Institutional Review.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12:5–11PubMedGoogle Scholar
  2. 2.
    Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159:327–333CrossRefGoogle Scholar
  3. 3.
    Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G (2014) Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J Community Support Oncol 12:401–406CrossRefGoogle Scholar
  4. 4.
    Beijers AJ, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, van de Poll-Franse LV, Mols F (2016) Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer 24:2411–2420CrossRefGoogle Scholar
  5. 5.
    Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Annals of oncology : official journal of the European Society for Medical Oncology 23:2020–2027CrossRefGoogle Scholar
  6. 6.
    Centers for Medicare & Medicaid Services (2008 ) Minimum data set version 2.0 for nursing home resident assessment and care screening. In: Editor (ed)^(eds) Book Minimum Data Set Version 2.0 for Nursing Home Resident Assessment and Care creening. CMS, CityGoogle Scholar
  7. 7.
    Chan CS, Slaughter SE, Jones CA, Wagg AS (2015) Greater independence in activities of daily living is associated with higher health-related quality of life scores in nursing home residents with dementia. Healthcare (Basel, Switzerland) 3:503–518Google Scholar
  8. 8.
    Chowdhury D, Patel N (2006) Approach to a case of autonomic peripheral neuropathy. J Assoc Physicians India 54:727–732PubMedGoogle Scholar
  9. 9.
    Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20:877–881CrossRefGoogle Scholar
  10. 10.
    Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, Pijnenborg JM, van de Poll-Franse LV (2014) Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 135:510–517CrossRefGoogle Scholar
  11. 11.
    Ghose A, Tariq Z, Taj A, Chaudhary R (2011) Acute dyspnea from treatment of AL amyloidisis with bortezomib. Am J Ther 18:e123–e125CrossRefGoogle Scholar
  12. 12.
    Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, American Society of Clinical O (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967CrossRefGoogle Scholar
  13. 13.
    Hong JS, Tian J, Wu LH (2014) The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol 21:174–180CrossRefGoogle Scholar
  14. 14.
    Hwang KH, Cho OH, Yoo YS (2016) Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. Eur J Oncol Nurs 21:215–222CrossRefGoogle Scholar
  15. 15.
    Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA 185:914–919CrossRefGoogle Scholar
  16. 16.
    Kim KY, Lee SH, Kim JH, Oh PJ (2015) Disturbance in ADL from chemotherapy-induced peripheral neuropathy and quality of life in cancer patients: the mediating effect of psychological distress. J Korean Acad Nurs 45:661–670CrossRefGoogle Scholar
  17. 17.
    Knoerl R, Chornoby Z, Smith EML (2018) Estimating the frequency, severity, and clustering of SPADE symptoms in chronic painful chemotherapy-induced peripheral neuropathy. Pain Manag Nurs 19:354–365CrossRefGoogle Scholar
  18. 18.
    Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787–2799CrossRefGoogle Scholar
  19. 19.
    McMillan SC, Mahon M (1994) Measuring quality of life in hospice patients using a newly developed Hospice Quality of Life Index. Qual Life Res 3:437–447CrossRefGoogle Scholar
  20. 20.
    McMillan SC, Small BJ (2002) Symptom distress and quality of life in patients with cancer newly admitted to hospice home care. Oncol Nurs Forum 29:1421–1428CrossRefGoogle Scholar
  21. 21.
    McMillan SC, Weitzner M (1998) Quality of life in cancer patients: use of a revised Hospice Index. Cancer Pract 6:282–288CrossRefGoogle Scholar
  22. 22.
    McMillan SC, Small BJ, Haley WE (2011) Improving hospice outcomes through systematic assessment: a clinical trial. Cancer Nurs 34:89–97CrossRefGoogle Scholar
  23. 23.
    Mohammed J, Meeus M, Derom E, Da Silva H, Calders P (2015) Evidence for autonomic function and its influencing factors in subjects with COPD: a systematic review. Respir Care 60:1841–1851CrossRefGoogle Scholar
  24. 24.
    Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699–2707CrossRefGoogle Scholar
  25. 25.
    Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O (2015) Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer surviv 9:512–522CrossRefGoogle Scholar
  26. 26.
    Nho JH, Reul Kim S, Nam JH (2017) Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy. Eur J Oncol Nurs 30:8–14CrossRefGoogle Scholar
  27. 27.
    Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336CrossRefGoogle Scholar
  28. 28.
    Rha SY, Lee J (2017) Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. Support Care Cancer 25:1519–1527CrossRefGoogle Scholar
  29. 29.
    Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 20:3355–3364CrossRefGoogle Scholar
  30. 30.
    Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Jama 309:1359–1367CrossRefGoogle Scholar
  31. 31.
    Smith EM, Campbell G, Tofthagen C, Kottschade L, Collins ML, Warton C, Ghosh B, Ronis DL, Mallory GA, Visovsky C (2014) Nursing knowledge, practice patterns, and learning preferences regarding chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 41:669–679CrossRefGoogle Scholar
  32. 32.
    Stubblefield MD, McNeely ML, Alfano CM, Mayer DK (2012) A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer 118:2250–2260CrossRefGoogle Scholar
  33. 33.
    Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14:E22–E28CrossRefGoogle Scholar
  34. 34.
    Tofthagen C, McMillan SC (2010) Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer. Cancer Nurs 33:437–444CrossRefGoogle Scholar
  35. 35.
    Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21:3307–3313CrossRefGoogle Scholar
  36. 36.
    Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manag 25:420–429CrossRefGoogle Scholar
  37. 37.
    Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157:560–568CrossRefGoogle Scholar
  38. 38.
    Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C (2007) Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11:901–913CrossRefGoogle Scholar
  39. 39.
    Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S (2017) Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 35:2604–2612CrossRefGoogle Scholar
  40. 40.
    Zhang X, Chen WW, Huang WJ (2017) Chemotherapy-induced peripheral neuropathy. Biomed Rep 6:267–271CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Mayo Clinic FloridaJacksonvilleUSA
  2. 2.University of South Florida, College of NursingTampaUSA

Personalised recommendations